Multiple myeloma (MM) has double the incidence rate and younger age of presentation in African-Americans (AA) compared with Caucasians. 1 Significant improvements in the treatment of MM have been made with the advent of the immunomodulatory drugs (IMIDs), such as thalidomide and lenalidomide, and the proteosome inhibitor bortezomib when used both as front line and salvage therapies. 2, 3 Although comparable outcomes of AA and non-AA patients with standard chemotherapy were previously demonstrated, it is not known whether IMIDs or bortezomib can improve the outcome in MM patients of different ethnicity. 4 To address this question, we consecutively analyzed 56 newly diagnosed MM patients (26 AA, 30 non-AA) who received induction therapy at our institution from January 2003 to June 2011. All of the patients received induction therapy with one or more of the new agents (IMIDs or bortezomib) in addition to either dexamethasone or prednisone (Table 1) . Of 56 patients, 48 then received high-dose melphalan followed by auto-SCT. 5 Patients were staged according to the Durie-Salmon criteria 6 and prognostic criteria according to b 2 -microglobulin, and serum albumin levels were also analyzed. 7 Response criteria were assessed according to the International Uniform Response criteria. 8 Baseline characteristics in AA and non-AA MM patients (Table 1) were comparable at presentation with the exception of the serum b 2 -microglobulin level that was 45.5 mg/L in 65% AA patients and 29% in non-AA patients (P ¼ 0.024). The two groups received comparable type and median number of induction regimens (range 1-3 AA and 1-4 non-AA, respectively) before achieving a clinical response ( Table 1 ). The total number of cycles of treatment during induction ranged between 3 and 12 in AA and 3 and 16 in non-AA (P ¼ NS). The response rates to induction therapy with regimens incorporating a novel agent were similar between AA and non AA (Table 1) . However, the rate of progressive disease (PD) was significantly lower in AA compared with non-AA (P ¼ 0.03). Of 56 patients, 8 were not eligible for allo-SCT owing to co-morbidities/advanced age (n ¼ 7; 4 AA and 3 non-AA) or insurance denial (n ¼ 1 non-AA). Of the 48 who received an ASCT, 45 were analyzed (21 AA, 24 non-AA). The remaining three were not included in the analysis for the following reasons: lost to follow-up (n ¼ 2; 1 AA and 1 non-AA) and TRM (n ¼ 1 non-AA).
After transplant, we observed comparable response rates and rates of progressive disease between AA and non-AA (Table 1) . At a median follow-up of 37 months (range: 7-125 months), the relapse rate was 59% in AA and 46% in non-AA patients (P ¼ NS). Among 56 patients in the study, 5 deaths were observed and all occurred in the non-AA group. Causes of death were disease progression in four patients and cerebrovascular accident in one patient. Disease-free survival was 28 months in AA and 17 months in non-AA (P ¼ NS) and the median time to relapse was 13 months in AA and 10 months in non-AA (P ¼ NS) (Figure 1a) . Median overall survival has not been reached yet in either group (Figure 1b) . Rates of grade 3-4 toxicity experienced during induction therapy were similar between AA and non-AA (48% vs 50%, respectively). These toxicities resulted in dose reductions in 13% of AA and 10% of non-AA patients and a change in the induction regimen in 26% of AA and 23% of non-AA patients.
In this study, we observed that the use of the novel agents, IMIDs or bortezomib alone or in combination, is equally beneficial in AA and non-AA patients. Potential differences in the biology of MM in AA have been theorized based on differences in incidence and age of presentation. Interestingly, a significantly greater median b2-microglobulin serum level was observed in AA patients despite having similar serum creatinine levels. In our study, this may have conferred a worse prognosis to AA patients although it is not known if it may be related to a biologic difference or not. In addition, it may raise the question of whether the time between initial signs or symptoms and actual diagnosis may vary in different patient populations. Despite higher levels of b2-microglobulin in this study, AA patients had an overall response comparable to non-AA after induction treatment with IMIDs and/ or bortezomib. Most of the patients in AA and non-AA groups also received high-dose melphalan chemotherapy followed by ASCT and the overall duration of response was also comparable. Our findings seem to be consistent with two recent population studies analyzing the outcome of AA and Caucasian myeloma patients. Rohatgi et al. 9 compared chemotherapy use and survival based on ethnicity. They found that although AA were 23% less likely to receive chemotherapy, the survival benefit to chemotherapy, stratified by age, gender and comorbidity was comparable between AA (hazard ratio ¼ 0.72; 95% CI, 0.61-0.86) and Caucasians (0.63; 95% CI, 0.58-0.67). Another study by Waxman et al. 10 compared survival rates between AA and non-AA during different eras of therapy. Interestingly, disease-specific and relative survival rates were consistently higher in AA than Caucasians over the entire study period. However, Caucasians significantly improved their 5-year relative survival rates over the time periods whereas nonsignificant improvements were seen in AA. These findings could be due to different sensitivities to new agents between AA and non-AA. Alternatively, the decreases in survival improvement in the AA cohort may have been due to differences in access to care. We favor the latter hypothesis based on results observed in our center where both AA and non-AA patients have equal access to care. In our previous study, 4 the overall response rate after induction treatment and disease-free survival after ASCT in AA patients was 51% and 21 months, respectively, whereas in this current study, they are 92% and 28 months, respectively, consistent with improvements conferred by the newer myeloma agents followed by allo-SCT.
Our results, although in a limited number of patients, suggest that IMIDs and/or bortezomib obtain good and comparable responses in AA and non-AA MM patients, and these responses are further improved with auto-SCT in both patient groups. At a median follow-up of 37 months, median OS was not reached for either group. Disease-free survival and OS were analyzed using the Kaplan-Meier method and differences were compared using the Log-rank test.
